However, since insulin treatment should be avoided while treating elderly type 2 diabetes patients to reduce the risks of hypoglycemia, a combination of SGLT2 inhibitors, GLP-1 agonists, and other kinds of OHA might be necessary to reach appropriate sugar levels. Here, SLC5A2 is linked to type 2 diabetes mellitus.